|Science Reporters Briefing:
New Advances in Parkinsonís Research and Treatment
||The National Institute of Neurological Disorders and Stroke
(NINDS) in partnership with the Parkinsonís community is bringing together
a panel of leading physicians, scientists, and caregivers to provide an
overview of the newest advances in Parkinsonís disease. Researchers will
discuss genetic aspects of the disease, new approaches to therapeutics,
and environmental and other factors that may impact onset of Parkinsonís.
Panelists will discuss their work and respond to questions from the audience.
||After Alzheimerís disease, Parkinsonís is the most common
neurodegenerative disorder. There are an estimated 6.3 million people worldwide
suffering from Parkinson's disease. Because of the aging world population,
and given that the number of older Americans will more than double to 70
million by 2030, now is the time to begin gaining a better understanding
of diseases, such as Parkinsonís, that have a significant impact on older
||Experts in Parkinsonís disease will make brief remarks.
A session for questions and answers will follow each speaker.
- Story Landis, Ph.D., Director, NINDS
- J. Timothy Greenamyre, M.D., Ph.D., University of Pittsburgh Medical Center,
Environmental Influences and Parkinsonís Disease (PD)
- Robert L. Nussbaum, M.D., National Human Genome Research Institute, Genetics
- Peter T. Lansbury, Jr., Ph.D., Brigham and Womenís Hospital, Drug Discovery
- Clive Svendsen, M.D., University of Wisconsin-Madison, Future Therapeutic
- Monique Giroux, M.D., The Cleveland Clinic Foundation, Caring for Patients
with PD Across the Clinical Spectrum
- Morton Kondracke, Author of Saving Milly, Caregiverís Perspective
||Thursday, October 20, 2005, 10:00 a.m. ET
||The Dana Center 900 15th St, NW, Washington, DC
Mark your calendar!
The first World Parkinson Congress will be held February 22-26, 2006, in Washington,
D.C. For more information, visit www.worldpdcongress.org.
The NINDS, a component of the National Institutes of Health (NIH) within the U.S.
Department of Health and Human Services, is the nationís primary supporter of basic,
translational, and clinical research on the brain and nervous system. The NINDS aims
to reduce the burden of neurological disease among all Americans.
The National Institutes of Health (NIH) &8212; The Nation's Medical Research Agency — includes
27 Institutes and Centers and is a component of the U. S. Department of Health and
Human Services. It is the primary Federal agency for conducting and supporting basic,
clinical, and translational medical research, and it investigates the causes, treatments,
and cures for both common and rare diseases. For more information about NIH and its
programs, visit http://www.nih.gov.